All questionsSpecific populations: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection5 questions · 3 sourcesSpecific populationsIs Biktarvy safe for older adults?“Clinical trials in virologically-suppressed participants (Trials 4449, 1844, and 1878) included 111 participants aged 65 years and over who received BIKTARVY, including 86 patients from an open-label, single-arm trial of participants aged 65 years and over who were switched from their previous antiretroviral regimen to BIKTARVY [see Clinical Studies (14.3)]. Of the total number of BIKTARVY-treated patients in these trials, 100 (90%) were 65 to 74 years of age, and 11 (10%) were 75 to 84 years of age. No overall differences in safety or effectiveness were observed between elderly participants and adults between 18 and less than 65 years of age, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.” (opens the source at this quote in a new tab)CopyFlag“Study 4449 ARs (All Grades) Reported in ≥1% of Virologically Suppressed Adults Aged ≥65 Years Through Week 96§ BIKTARVY (N=86) Abdominal discomfort, % 1.2 Abnormal feces, % 1.2 Constipation, % 1.2 Dizziness, % 1.2 Gamma-glutamyl transferase increased, % 1.2 Headache, % 1.2 Insomnia, % 1.2 Irritability, % 1.2 Myalgia, % 1.2 Pruritus, % 1.2 Sleep disorder, % 1.2 Tendonitis, % 1.2 Weight increased, % 1.2 §Frequencies of ARs are based on all adverse events attributed to trial drugs by the investigator. Through Week 96, there were 2 (2.3%) Grade 3 study drug-related AEs in adults aged ≥65 years14” (opens the source at this quote in a new tab)CopyFlagCan Biktarvy be used in people with kidney disease or on dialysis?“Renal impairment: For patients weighing ≥25 kg, not recommended in patients with CrCl 15 to <30 mL/min, or <15 mL/min who are not receiving chronic hemodialysis, or <15 mL/min who are receiving chronic hemodialysis and have no antiretroviral treatment history. For patients weighing ≥14 kg to <25 kg, not recommended in patients with CrCl <30 mL/min.” (opens the source at this quote in a new tab)CopyFlag“The pharmacokinetics, safety, virologic and immunologic responses of FTC and TAF (components of BIKTARVY) were evaluated in a single arm, open-label trial (Trial 1825) in virologically-suppressed adults with ESRD (estimated creatinine clearance of less than 15 mL/min) on chronic hemodialysis treated with FTC+TAF in combination with elvitegravir and cobicistat as a fixed-dose combination tablet for 96 weeks (N=55). In an extension phase of Trial 1825, 10 virologically-suppressed participants switched to BIKTARVY and all remained virologically suppressed for 48 weeks [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.3)]. No dosage adjustment of BIKTARVY is recommended in patients with estimated creatinine clearance greater than or equal to 30 mL/min, or in virologically-suppressed adults (estimated creatinine clearance below 15 mL/min) who are receiving chronic hemodialysis. On days of hemodialysis, administer the daily dose of BIKTARVY after completion of hemodialysis treatment [see Dosage and Administration (2.2)] BIKTARVY is not recommended in patients with estimated creatinine clearance of below 30 mL/min, by Cockcroft-Gault, or patients with ESRD (estimated creatinine” (opens the source at this quote in a new tab)CopyFlag“clearance below 15 mL/min) who are not receiving chronic dialysis, or patients with no antiretroviral treatment history and ESRD who are receiving chronic dialysis, as the safety and/or efficacy of BIKTARVY has not been established in these populations [see Dosage and Administration (2.4), Warnings and Precautions (5.4), and Clinical Pharmacology (12.3)].” (opens the source at this quote in a new tab)CopyFlagCan Biktarvy be used in people with liver impairment?“No dosage adjustment of BIKTARVY is recommended in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. BIKTARVY has not been studied in patients with severe hepatic impairment (Child-Pugh Class C). Therefore, BIKTARVY is not recommended for use in patients with severe hepatic impairment [see Dosage and Administration (2.4), and Clinical Pharmacology (12.3)].” (opens the source at this quote in a new tab)CopyFlagCan Biktarvy be taken during pregnancy?“Pregnancy: BIKTARVY is recommended in pregnant individuals who are virologically suppressed on a stable ARV regimen with no known substitutions associated with resistance to any of the individual components of BIKTARVY. Lower plasma exposures of BIKTARVY were observed during pregnancy; therefore, viral load should be monitored closely during pregnancy. An Antiretroviral Pregnancy Registry (APR) has been established. Available data from the APR for BIC, FTC, or TAF show no difference in the rates of birth defects compared with a US reference population.” (opens the source at this quote in a new tab)CopyFlag“BIKTARVY was evaluated in an open-label clinical trial of 33 virologically- suppressed (HIV-1 RNA < 50 copies/mL) pregnant adults with HIV-1 and no known substitutions associated with resistance to BIC, FTC, or TAF. Pregnant adults were administered BIKTARVY (containing 50 mg of BIC, 200 mg of FTC and 25 mg of TAF) once daily from the second or third trimester through postpartum. Exposures of BIC, FTC, and TAF were lower during pregnancy as compared to postpartum [see Clinical Pharmacology (12.3)]. All 32 adult participants who completed the study maintained viral suppression during pregnancy, at delivery, and through Week 18 postpartum. The median CD4+ cell count at baseline was 558 cells/μL, and the median change in CD4+ cell count from baseline to Week 12 postpartum was 159 cells/μL. All 29 neonate participants had negative/nondetectable HIV-1 PCR results at birth and/or at 4 to 8 weeks post-birth. The safety findings in this trial were consistent with other trials in adults. BIKTARVY was only studied in pregnant individuals who were virologically- suppressed, and lower plasma exposures of BIKTARVY were observed during pregnancy compared to post-partum. Therefore, BIKTARVY is recommended in pregnant individuals who are virologically-suppressed on a stable antiretroviral regimen with no known substitutions associated with resistance to any of the individual components of BIKTARVY.” (opens the source at this quote in a new tab)CopyFlagCan you breastfeed while taking Biktarvy?“Lactation: Individuals with HIV-1 should be informed of the potential risks of breastfeeding.” (opens the source at this quote in a new tab)CopyFlag“Data from the published literature report the presence of BIC, FTC, TAF, and tenofovir in human milk. There are no data on the effects of BIC on the breastfed child. Data from the published literature have not reported adverse effects of FTC or TAF on a breastfed child. There are no data on the effects of BIC, FTC or TAF on milk production. Potential risks of breastfeeding include: (1) HIV-1 transmission to HIV-1–negative infants; (2) developing viral resistance in HIV-1–positive infants; and (3) adverse reactions in a breastfed infant similar to those seen in adults.” (opens the source at this quote in a new tab)CopyFlag